# # # Disclosures: Rohit Loomba, MD, is a consultant or advisory board member for Aardvark Therapeutics, Altimmune, Anylam/Regeneron, Amgen, Arrowhead Pharmaceuticals, AstraZeneca, Bristol-Myer Squibb, CohBar, Eli Lilly, Galmed, Gilead, Glympse bio, Hightide, Inipharma, Intercept, Inventiva, Ionis, Janssen Inc., Madrigal, Metacrine, Inc., NGM Biopharmaceuticals, Novartis, Novo Nordisk, Merck, Pfizer, Sagimet, Theratechnologies, 89 bio, Terns Pharmaceuticals and Viking Therapeutics
How do clinicians diagnose GLP-1-related gastroparesis or intestinal slowing
132 Jimenez-JimenezF
Pharmacological GLP-1RA Action Key Mechanistic Distinctions A comprehensive review published in Cell Metabolism reviewed circuits engaged by endogenous versus pharmacological GLP-1 action, highlighting key GLP-1R-positive cell types and pathways transducing metabolic and non-glycaemic GLP-1 signals
The cellular redox state, as defined by the GSH/GSSG ratio, is not merely a passive indicator of stress but an active modulator of cellular signaling